Experimental Capivasertib Seems Promising for Advanced-Stage, Hormone Receptor-Positive, HER2-Negative Breast Cancer

episode

Breastcancer.org Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Full Show — September 22, 2026 2h 46m · 22 Sep 2026 · Rahimi & Grote Show

PDB Afternoon Bulletin | September 22nd, 2026: Tehran Offers To Reopen Hormuz & North Korea’s New Weapon 15 min · 22 Sep 2026 · The President's Daily Brief

US hits out at Aus opt-out laws + The Houthis vs Saudi Arabia explained 28 min · 22 Sep 2026 · The Briefing

Bears quarterback Tyson Bagent lands in concussion protocol (Hour 4) 40 min · 22 Sep 2026 · Rahimi & Grote Show

TAFS Unplugged: Iceage 14 min · 22 Sep 2026 · The Adam Friedland Show

'Lanterns' Episode 6 Deep Dive | House of R 1h 41m · 22 Sep 2026 · House of R

Report any issue

Source

Recorded15 Dec 2022

Publisherfeeds.megaphone.fm ↗

Handlerec:11088146

Show notes

Researchers are always looking for new treatments for advanced-stage breast cancer. Dr. Nicholas Turner explains the results of the CAPitello-291 trial, looking capivasertib, an experimental targeted therapy medicine, in combination with Faslodex (chemical name: fulvestrant) as a treatment for advanced-stage, hormone receptor-positive, HER2-negative breast cancer that has become resistant to the aromatase inhibitors. Listen to the episode to hear Dr. Turner explain: how capivasertib works the results of the CAPitello-291 trial how capivasertib worked on cancers previously treated with a CDK4/6 inhibitor

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in